The technological Ingeniatrics and Aradigm, a pulmonary pharmaceutical industry pioneer, signed a new agreement in February, 2012. By this, Aradigm is licensed by Ingeniatrics to develop and operate in the field of medicaments administration to or through respiratory tract using flow focusing and flow blurring technology.
Aradigm's multidisciplinary team led by Dr. Igor Gonda and David Cipolla has experience at developing a variety of pharmaceutical and health care products and launching them to the market.
Aradigm gets an exclusive, world-wide license on Ingeniatrics's technology to develop, make, use, sell, and offer for sale drugs delivered by inhalation, including drugs for severe respiratory disease treatment.
Enhanced Licensees support:
Once Ingeniatrics had reached agreements with Flow Pharma and the University of Seville, this agreement with Aradigm confirms Ingeniatrics’ control and strengthen its position. Due to this, the microencapsulation company offers a stable, safe and simplified framework to all its licensees and their sub- licensees in order to ensure their business model.
Optimized Intellectual Property management:
Ingeniatrics is currently focused on scaling its technologies up, enhancing its capacity to offer services and products making use of its brand-new three hundred square meters microencapsulation pilot-plant, which is made up of three separate rooms for Pharma (registered as "cleanroom" or ISO 7 white room), Food and Chemistry.
By virtue of this agreement, Ingeniatrics will be the only Flow Focusing® and Flow Blurring® patents manager world-wide. Alongside with other previous agreements, this one grants to Ingeniatrics a solid base to strategize the best course of action to protect its microencapsulation and nebulization Intellectual Property.